Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $190.00

Protagonist Therapeutics (NASDAQ:PTGX) had its target price boosted by BMO Capital Markets from $178.00 to $190.00 in a research report released on Tuesday morning, Marketbeat.com reports. BMO Capital Markets currently has an outperform rating on the stock.

A number of other brokerages have also weighed in on PTGX. Weiss Ratings upgraded Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Johnson Rice set a $165.00 target price on Protagonist Therapeutics in a research report on Friday, July 17th. Truist Financial increased their price target on Protagonist Therapeutics from $145.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Citizens Jmp lifted their price objective on Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday, July 1st. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $147.13.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ:PTGX opened at $148.80 on Tuesday. The firm has a fifty day moving average price of $140.71 and a 200 day moving average price of $114.52. Protagonist Therapeutics has a fifty-two week low of $54.50 and a fifty-two week high of $160.81. The firm has a market cap of $9.63 billion, a price-to-earnings ratio of 144.47 and a beta of 1.80.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.02. The company had revenue of $213.47 million during the quarter, compared to analysts’ expectations of $212.03 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The firm’s revenue was up 3746.8% compared to the same quarter last year. As a group, research analysts predict that Protagonist Therapeutics will post 4.22 earnings per share for the current year.

Insider Transactions at Protagonist Therapeutics

In related news, Director William D. Waddill sold 9,000 shares of the stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total value of $1,061,460.00. Following the completion of the transaction, the director owned 7,825 shares of the company’s stock, valued at approximately $922,880.50. This trade represents a 53.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 34,239 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $148.52, for a total value of $5,085,176.28. Following the completion of the transaction, the chief executive officer owned 523,478 shares of the company’s stock, valued at approximately $77,746,952.56. This represents a 6.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 118,000 shares of company stock worth $16,921,379. Insiders own 5.19% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Several institutional investors have recently modified their holdings of PTGX. Johnson & Johnson bought a new position in shares of Protagonist Therapeutics during the second quarter valued at approximately $300,220,852. NEXTBio Capital Management LP bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth approximately $20,055,000. Deutsche Bank AG purchased a new position in Protagonist Therapeutics during the 2nd quarter valued at $17,387,000. Stempoint Capital LP grew its position in Protagonist Therapeutics by 22.1% in the 1st quarter. Stempoint Capital LP now owns 72,577 shares of the company’s stock valued at $7,650,000 after acquiring an additional 13,147 shares during the last quarter. Finally, Clearbridge Investments LLC purchased a new stake in Protagonist Therapeutics in the fourth quarter worth $42,783,000. 98.63% of the stock is owned by institutional investors.

Key Stories Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: BMO raised its price target to $190: BMO Capital Markets boosted its target from its prior level to $190, signaling additional potential upside and reinforcing investor confidence in Protagonist’s outlook. BMO Capital Markets Boosts Protagonist Therapeutics Price Target to $190.00
• Positive Sentiment: Analyst sentiment remains favorable: Recent healthcare-stock roundups highlighted Protagonist as a bullishly viewed company, adding to the positive research backdrop around PTGX. Analysts Are Bullish on Top Healthcare Stocks Analysts Are Bullish on These Healthcare Stocks
• Positive Sentiment: HC Wainwright maintains a Buy rating: The firm reiterated a $170 price target. Although it expects losses in the first three quarters of 2027, its estimates include a smaller fourth-quarter loss, while the current-year consensus remains positive at $4.22 per share. HC Wainwright Protagonist Therapeutics Estimates
• Neutral Sentiment: Investor conferences scheduled: Protagonist announced that CEO Dinesh V. Patel will participate in two investment-bank conferences in September. The events may provide updates on the company’s pipeline and strategy but do not immediately change fundamentals. Protagonist Therapeutics to Participate in Two Investment Bank Conferences
• Negative Sentiment: Valuation concerns remain: One report argued that PTGX could be overvalued following FDA approval-related news. With the stock trading at a high earnings multiple and near its 12-month peak, investors may be vulnerable to profit-taking if future results do not justify the premium valuation. Protagonist Therapeutics Stock Could Be Overvalued Following FDA Approval News

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.